JPRN-UMIN000003976已完成4 期
Prospective and Retrospective Multicenter Cohort Study of Patients With Chronic Hepatitis C Treated by Peginterferon Alfa-2b Plus Ribavirin - Prospective and Retrospective Multicenter Cohort Study of Patients With Chronic Hepatitis C Treated by Peginterferon Alfa-2b Plus Ribavirin
Department of Gastroenterology The University of Tokyo Hospital0 个研究点目标入组 150 人开始时间: 2010年8月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
The rate of SVR was 55%.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Any contraindication to peginterferon alfa-2b + ribavirin therapy
研究者
相似试验
已完成
不适用
A prospective multicenter study for characterization of renal function G1b CHC patients with CKD-3 treated with elbasvir plus grazoprevirJPRN-UMIN000026542Kyushu University80
进行中（未招募）
2 期
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)Hepatitis BNCT04954859GlaxoSmithKline360
进行中（未招募）
不适用
A Prospective, Multi-center, Longitudinal Cohort Study of Dermagraft® in Subjects with Venous Leg Ulcers: A Long-term Follow-up to the DEVO-Trial - Dermagraft® in Venous Leg Ulcers (DEVO Follow up)EUCTR2010-019887-35-DEAdvanced BioHealing Inc180
进行中（未招募）
1 期
A Prospective, Multi-center, Longitudinal Cohort Study of Dermagraft® in Subjects with Venous Leg Ulcers: A Long-term Follow-up to the DEVO-Trial - Dermagraft® in Venous Leg Ulcers (DEVO Follow up)Venous leg ulcersMedDRA version: 9.1 Level: LLT Classification code 10024134 Term: Leg ulcer (exc varicose)EUCTR2010-019887-35-GBAdvanced BioHealing Inc180
进行中（未招募）
不适用
A Prospective, Multi-center, Longitudinal Cohort Study of Dermagraft® in Subjects with Venous LegUlcers: A Long-term Follow-up to the DEVO-Trial - Dermagraft® in Venous Leg Ulcers (DEVO Follow up)Venous leg ulcersMedDRA version: 14.1Level: LLTClassification code 10024134Term: Leg ulcer (exc varicose)System Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2010-019887-35-EEShire Regenerative Medicine, Inc.180